Locoregional Recurrence Patterns After Mastectomy and Doxorubicin-Based Chemotherapy: Implications for Postoperative Irradiation
Top Cited Papers
- 15 August 2000
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (15) , 2817-2827
- https://doi.org/10.1200/jco.2000.18.15.2817
Abstract
PURPOSE: The objective of this study was to determine locoregional recurrence (LRR) patterns after mastectomy and doxorubicin-based chemotherapy to define subgroups of patients who might benefit from adjuvant irradiation. PATIENTS AND METHODS: A total of 1,031 patients were treated with mastectomy and doxorubicin-based chemotherapy without irradiation on five prospective trials. Median follow-up time was 116 months. Rates of isolated and total LRR (± distant metastasis) were calculated by Kaplan-Meier analysis. RESULTS: The 10-year actuarial rates of isolated LRR were 4%, 10%, 21%, and 22% for patients with zero, one to three, four to nine, or ≥ 10 involved nodes, respectively (P < .0001). Chest wall (68%) and supraclavicular nodes (41%) were the most common sites of LRR. T stage (P < .001), tumor size (P < .001), and ≥ 2-mm extranodal extension (P < .001) were also predictive of LRR. Separate analysis was performed for patients with T1 or T2 primary disease and one to three involved nodes (n = 404). Those with fewer than 10 nodes examined were at increased risk of LRR compared with those with ≥ 10 nodes examined (24% v 11%; P = .02). Patients with tumor size greater than 4.0 cm or extranodal extension ≥ 2 mm experienced rates of isolated LRR in excess of 20%. Each of these factors continued to significantly predict for LRR in multivariate analysis by Cox logistic regression. CONCLUSION: Patients with tumors ≥ 4 cm or at least four involved nodes experience LRR rates in excess of 20% and should be offered adjuvant irradiation. Additionally, patients with one to three involved nodes and large tumors, extranodal extension ≥ 2 mm, or inadequate axillary dissections experience high rates of LRR and may benefit from postmastectomy irradiation.Keywords
This publication has 45 references indexed in Scilit:
- Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trialPublished by Elsevier ,1999
- Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant ChemotherapyNew England Journal of Medicine, 1997
- The role of radiotherapy in the management of operable locally advanced breast carcinomaCancer, 1997
- Effects of Radiotherapy and Surgery in Early Breast Cancer — An Overview of the Randomized TrialsNew England Journal of Medicine, 1995
- Adjuvant radiation therapy versus surgery alone in operable breast cancer: long-term follow-up of a randomized clinical trialRadiotherapy and Oncology, 1993
- The Total Incidence of Loco-Regional Recurrence in a Randomized Trial of Breast Cancer Tnm Stage Ii the South Sweden Breast Cancer TrialActa Oncologica, 1993
- Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: a South-Eastern Cancer Study Group (SEG) trialEuropean Journal Of Cancer, 1992
- Evaluation of radiotherapy in high-risk breast cancer patients: Report from the Danish Breast Cancer Cooperative Group (DBCG 82) trialInternational Journal of Radiation Oncology*Biology*Physics, 1990
- Postoperative radiotherapy in breast cancer—long-term results from the Oslo studyInternational Journal of Radiation Oncology*Biology*Physics, 1986
- Adjuvant radiotherapy and chemotherapy in breast cancerBritish Journal of Surgery, 1986